1. Understand challenges in drugging large protein-protein interactions.
2. Understand how combination therapies can widen the therapeutic window if delivered to the target cells simultaneously.
3. Understand how drugging the BCL-2 family of proteins may overcome cell death resistance in refractory malignancies
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation